Unlocking the Value of Meitheal Xentria's Transformative Platform

责全球合作伙伴关系、供应链和产品开发：Xentria.Inc创始总裁. Victoria Wohlfeil Cherry 总法律顺间兼公司秘书. Sagent Pharmaceuticals法律总顾间兼助理秘书；Xentria Xentria Inc./Meitheal. Pharmaceuticals Inc. In clinical trials. Molecule. Innovator product (company) Biosimilars. Company. Status. Omalizumab. Xolair® ( ... ... Meitheal, Organon, Pheon, Remegen, Samsung Bioepis, Sandoz, Sanyou, Shionogi, Sirnaomics, SK Bioscience, Xentria, Zymedi. Read More · Regulatory actions ... 健友股份(603707)6月27日晚间公告，公司全资子公司香港健友（被许可方代表）及香港健友控股子公司Meitheal（被许可方）拟与Xentria签署许可协议，Xentria授予被许可方 ... Xentria and Meitheal Pharmaceuticals Announce Exclusive Licensing Agreement for XTMAB-16 in North America. 27 June 2023. Press Release: Positive topline Phase ... In a deal valued in excess of $600 million, Meitheal will obtain sole rights to market the biologic in North America, with Xentria continuing to ... Xentria has entered a licensing agreement with Meitheal Pharmaceuticals to market XTMAB-16 for pulmonary sarcoidosis in North America. Perkins Coie Advises Xentria in Multi-Year Licensing Agreement with Meitheal to Market Xentria's Novel Biologic to Treat Pulmonary Sarcoidosis · Home ... 2023年6月27日，临床阶段生物技术公司Xentria Inc.与Meitheal Pharmaceuticals, Inc.宣布达成一项多年期独家许可协议，在北美将其主要候选药物和新型 ... Xentria. Meitheal Pharma (King Friend Industry). XTMAB-16. - αTNFα mAb. 유육종증 (Sarcoidosis). 임상1상. 680. 21. 6/28. Unlearn. QurAlis.